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Summary
Background Human and animal prion diseases are under genetic control, but apart from PRNP (the gene that encodes 
the prion protein), we understand little about human susceptibility to bovine spongiform encephalopathy (BSE) 
prions, the causal agent of variant Creutzfeldt–Jakob disease (vCJD).
Methods We did a genome-wide association study of the risk of vCJD and tested for replication of our ﬁ ndings in 
samples from many categories of human prion disease (929 samples) and control samples from the UK and Papua 
New Guinea (4254 samples), including controls in the UK who were genotyped by the Wellcome Trust Case Control 
Consortium. We also did follow-up analyses of the genetic control of the clinical phenotype of prion disease and 
analysed candidate gene expression in a mouse cellular model of prion infection.
Findings The PRNP locus was strongly associated with risk across several markers and all categories of prion disease 
(best single SNP [single nucleotide polymorphism] association in vCJD p=2·5×10–¹⁷; best haplotypic association in vCJD 
p=1×10–²⁴). Although the main contribution to disease risk was conferred by PRNP polymorphic codon 129, another 
nearby SNP conferred increased risk of vCJD. In addition to PRNP, one technically validated SNP association upstream 
of RARB (the gene that encodes retinoic acid receptor beta) had nominal genome-wide signiﬁ cance (p=1·9×10–⁷). A 
similar association was found in a small sample of patients with iatrogenic CJD (p=0·030) but not in patients with 
sporadic CJD (sCJD) or kuru. In cultured cells, retinoic acid regulates the expression of the prion protein. We found an 
association with acquired prion disease, including vCJD (p=5·6×10–⁵), kuru incubation time (p=0·017), and resistance to 
kuru (p=2·5×10–⁴), in a region upstream of STMN2 (the gene that encodes SCG10). The risk genotype was not associated 
with sCJD but conferred an earlier age of onset. Furthermore, expression of Stmn2 was reduced 30-fold post-infection in 
a mouse cellular model of prion disease. 
Interpretation The polymorphic codon 129 of PRNP was the main genetic risk factor for vCJD; however, additional 
candidate loci have been identiﬁ ed, which justiﬁ es functional analyses of these biological pathways in prion disease.
Funding The UK Medical Research Council.
Introduction
Prion diseases are transmissible, fatal, neurodegenerative 
conditions of human beings and animals that are caused 
by the autocatalytic misfolding of host-encoded prion 
protein (PrP).1 An epizootic prion disease, bovine 
spongiform encephalopathy (BSE), widely exposed the 
population of the UK (and, to a lesser extent, many other 
populations) to prion infection. The subsequent diagnosis 
of variant Creutzfeldt–Jakob disease (vCJD) in young 
British adults, and the experimental ﬁ nding that this was 
caused by BSE-like prions,2–4 resulted in a major public and 
animal health crisis. 
Although the number of recorded clinical cases of vCJD 
to date has been small (~200) in relation to the millions of 
people who were potentially exposed, how many individuals 
were infected is unclear. The clinically silent incubation 
period in human beings can exceed 50 years,5 and estimates 
of the prevalence of subclinical infection made on the basis 
of screening archived surgical specimens predicts that 
thousands of individuals in the UK are infected.6 Blood 
transfusion seems to be an eﬃ  cient route of secondary 
transmission7 but no screening test to ensure the safety of 
blood products is yet available. Case control studies have 
identiﬁ ed no unusual occupational, dietary, or other 
exposure to BSE prions among patients with vCJD,8 which 
suggests that genetic factors might be crucial. 
A known genetic factor for susceptibility to prion disease 
is the common single nucleotide polymorphism (SNP) at 
codon 129 in PRNP, the gene that encodes PrP in human 
beings. Here, either methionine (~60% allele frequency in 
Europeans) or valine is encoded.9 All patients with vCJD 
who have been genotyped are homozygous for methionine,10 
which represents the strongest association to date of a 
common genotype with any disease. Although this is a 
powerful eﬀ ect, about a third of the exposed UK population 
have this genotype. An important role for other genetic loci 
is supported by the results of mouse quantitative trait locus 
studies, which have identiﬁ ed many regions that are not 
linked to Prnp but control the highly variable prion disease 
incubation periods,11,12 including that of BSE prions.13 The 
importance to public health of understanding susceptibility 
to BSE prion infection in human beings is therefore clear. 
We undertook a genome-wide association study with 
100K and 500K Aﬀ ymetrix arrays with all available samples 
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from white British patients with vCJD (n=119) compared 
with our own and publicly available UK control data, which 
was genotyped by the Wellcome Trust Case–Control 
Consortium (WTCCC). Because all available vCJD samples 
from the UK were included in the discovery phase, we 
went on to compare the top-ranked SNP associations and 
additional SNPs at the PRNP locus with a large and diverse 
collection of patients with prion disease, including those 
with iatrogenic CJD (iCJD), sporadic CJD (sCJD), and 
kuru.  
Methods
Samples
Figure 1 shows the four tiers of genotyping in the study. 
Samples were obtained from 119 patients with vCJD 
(ten patients with probable vCJD and 109 patients with 
deﬁ nite vCJD) who were diagnosed at the National Prion 
Clinic (NPC), London, or the National CJD Surveillance 
Unit (NCJDSU), Edinburgh, between 1995 and 2005 
according to established criteria. Patients who acquired 
iatrogenic vCJD through blood transfusion were not 
included in this series. All patients with vCJD were thought 
to have acquired the disease in the UK and were of white 
British ethnic origin (60% were men; mean age of disease 
onset was 29·8 [SD 10·9] years).
Samples were obtained from 506 patients with probable 
or deﬁ nite sCJD diagnosed according to established criteria 
and from 28 patients with iCJD related to exposure to 
cadaver-derived growth hormone in the 1980s or earlier; 
these samples were obtained from the NPC or the NCJDSU 
or from other clinical colleagues in the UK. All patients 
were from the UK or elsewhere in northern Europe. 
Although most patients were of white British ethnic origin, 
and all patients of known non-white ethnic origin were 
excluded, this information was based on names and 
geographical location for some samples. 325 patients had 
pathologically conﬁ rmed sCJD and 181 patients had a 
diagnosis of probable sCJD with a high speciﬁ city according 
to published WHO criteria, although some of these 
patients might have had a neuropathological diagnosis 
made elsewhere.14 Mean age of disease onset was 68·2 
(SD 12·0) years for the patients with sCJD and 31·1 
(6·3) years for the patients with iCJD. 50% of the samples 
from patients with sCJD were from men. 
Before 1987, kuru surveillance was done by many 
diﬀ erent investigators; however, from 1987 to 1995 
surveillance was done solely by the Kuru Surveillance 
Team of the Papua New Guinea Institute of Medical 
Research. From 1996, kuru surveillance was strengthened: 
a ﬁ eld base and basic laboratory for sample processing and 
storage were established in the village of Waisa in the 
South Fore, and a wide collection of population control 
samples were taken.5 The samples from patients with kuru 
(n=151) were taken from young children, adolescents, and 
adults during the peak of the epidemic and from recent 
cases of kuru with long incubation times in elderly patients. 
The patients lived in the South Fore (n=53), North Fore 
(n=40), Gimi (n=3), and Keiagana (n=10) regions; linguistic 
group was not known in 45 patients. 
Elderly women who had been exposed to kuru were 
deﬁ ned as aged older than 50 years in 2000 and from a 
region that had been exposed to kuru: South Fore (n=74), 
North Fore (n=36), Gimi (n=13), and Keiagana (n=2). The 
modern-day healthy population from the exposed region 
was obtained by matching each elderly woman to at least 
two current residents of the same village who were aged 
less than 50 years in 2000. These mostly came from the 
South Fore, with some from the North Fore, and a small 
number of individuals from Gimi, Keiagana, and Yagaria 
linguistic groups, as indicated. First-degree relatives of the 
elderly women, identiﬁ ed by either genealogical data or 
microsatellite analysis, were excluded from these groups. 
155 samples were from volunteers recruited by the 
Medical Research Council Prion Unit from the National 
Blood Service (NBS). Information was collected about their 
sex, age, ethnic origin, and birthplace divided into 
12 regions. 90 samples genotyped with Aﬀ ymetrix arrays 
were selected to match the vCJD collection for white British 
ethnic origin, birthplace (by 12 regions in UK, each region 
was represented in patients and controls with the same 
ranking), and sex (proportion of men with vCJD was 60%, 
and the proportion of men in the NBS controls was 57%). 
 A further 575 UK control samples were obtained for the 
replication phases of the study (730 healthy controls in 
total) from the NBS (95 white, random, healthy young 
blood donors) and from the European Collection of Cell 
Cultures (ECACC) human random control DNA collection 
(480 blood donors of known age and sex). No selection was 
done in the replication phase of the study. Not all control 
samples were genotyped for all replication studies; 
however, there is no reason to expect signiﬁ cant genetic 
heterogeneity in our collections of UK blood donors based 
on analyses of the UK population done by the WTCCC and 
others.15 All UK control samples contained good quality 
unampliﬁ ed DNA. The mean age at sampling was 
38·7 (SD 10·8) years, and 51% were men. In addition, we 
used publicly available UK control data generated by the 
WTCCC. In brief, 1500 samples from the 1958 British 
Birth Cohort and 1500 samples from the UK Blood Service 
Control Group were genotyped with commercial Aﬀ ymetrix 
500K arrays with a Bayesian robust linear model with 
Mahalanobis distance (BRLMM) algorithm. We did not 
detect any duplicate individuals between the UK control 
collections nor any signiﬁ cant diﬀ erences in allele 
frequency between our in-house UK control collections or 
those genotyped by the WTCCC. 
The clinical and laboratory studies were approved by the 
local research ethics committee of University College 
London Institute of Neurology and National Hospital for 
Neurology and Neurosurgery and by the Medical Research 
Advisory Committee of the Government of Papua New 
Guinea. The full participation of the Papua New Guinea 
communities was established and maintained through 
discussions with village leaders, communities, families, 
For WTCCC genotype data see 
http://www.wtccc.org.uk/info/
access_to_data_samples.shtml
For more on the criteria see 
http://www.advisorybodies.doh.
gov.uk/acdp/tseguidance/
tseguidance_annexb.pdf
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and individuals. Most of the UK samples were obtained 
with written consent from patients or next of kin; however, 
where this was not available, for example, for archival vCJD 
tissue obtained at post-mortem examination, we obtained 
the speciﬁ c approval of our local ethics committee for the 
use of these samples in the research. 
Procedures
For the samples from patients with vCJD, genomic DNA 
was mostly extracted from peripheral blood, although 
45 samples were extracted from brain tissue. For a few 
samples, whole-genome ampliﬁ cation, either with a φ29 
protocol called multiple displacement ampliﬁ cation 
(MDA; Geneservice, Cambridge, UK; ten samples) or 
GenomePlex Complete Whole Genome Ampliﬁ cation Kit 
(WGA2; Sigma, UK; two samples) was necessary. 
For the samples from patients with sCJD or iCJD, whole-
genome ampliﬁ cation with either MDA in 138 samples or 
WGA2 in 29 samples was needed. Most of the samples 
from patients with sCJD and iCJD were extracted from 
blood, although DNA from eight samples in the iCJD 
group and 70 samples from the sCJD group was derived 
from brain tissue. 112 samples from patients with sCJD 
were sent as DNA to the MRC Prion Unit for analysis, 
most of which were extracted from blood. Genomic DNA 
was usually extracted from peripheral blood. PAXgene 
blood-derived RNA samples were also collected (Reanalytix, 
QIAGEN, UK).
DNA from degraded archival kuru sera was isolated by 
QIAamp Blood DNA minikit (QIAGEN, UK) followed by 
whole-genome ampliﬁ cation with WGA2 in all but seven 
samples. The validation of this process for the degraded 
kuru samples has been reported elsewhere.16 
Good-quality genomic DNA extracted from blood was 
available for 278 of 285 (98%) healthy controls from Papua 
New Guinea and 122 of 125 (98%) healthy elderly women 
with many exposures to kuru at mortuary feasts. All control 
samples from Papua New Guinea were extracted from 
blood. 
All DNA samples were checked for degradation on 1% 
agarose gel and stored at 50 ng/μL in low-concentration 
tris-EDTA buﬀ er.
Rocky Mountain Laboratory (RML) prion-infected mouse 
brain homogenate (0·001%) or mock-infected brain 
homogenate from wild-type CD-1 mice (0·001%) was used 
to infect GT-1 hypothalamic neuronal cells. 5000 cells were 
seeded into 96-well plates and incubated with either 
homogenate in standard growth medium (Opti-MEM 
supplemented with 10% fetal calf serum and 1% penicillin/
streptomycin  [Invitrogen, CA, USA]). The inoculum was 
removed after 3 days and the cells were split 1:8. Cells were 
then split 1:8 twice more at intervals of 3 days. High levels 
of prion infectivity were conﬁ rmed with the scrapie cell 
assay.17 Prion-infected and mock-infected cells were 
maintained in standard growth medium at 37ºC in 5% 
CO₂. Total RNA was extracted in triplicate with the RNeasy 
Midi kits (QIAGEN, UK) according to the manufacturer’s 
instructions, from prion-infected and mock-infected cells 
that had been grown on 10-cm-diameter plates. RNA was 
eluted in RNAase-free water and stored at –80ºC. RNA 
samples adjusted to a concentration of 250 ng in 5 μL were 
incubated at 50ºC for 30 mins with an equal volume of 
Glyoxyl (Ambion, Warrington, UK) loading dye containing 
ethidium bromide. Samples were run on a 1·5% agarose 
mini-gel in 1× NorthernMAx glyoxyl-based gel prep and 
running buﬀ er (Ambion) at 100 mV for 90 min to check 
sample integrity. RNA was then sent to AROS Applied 
Biotechnology AS (Denmark) for the following microarray 
analyses according to Aﬀ ymetrix standard protocols: ﬁ rst 
and second strand complementary DNA synthesis was 
done with the SuperScriptII System (Invitrogen) from 
5 μg RNA (a minor modiﬁ cation was made to the protocol 
by using an oligo-dT primer that contained a T7 RNA 
polymerase promoter site); labelled antisense RNA (cRNA) 
was prepared with the BioArray High Yield RNA Transcript 
Labelling Kit with biotin-labelled CTP and UTP (Enzo Life 
Sciences, NY, USA) and unlabelled NTPs. Unincorporated 
nucleotides were removed using RNeasy columns 
(QIAGEN). 15 μg of cRNA was fragmented, loaded on to 
the Aﬀ ymetrix mouse expression array 430_2.0 probe array 
cartridge, and hybridised for 16 h. Arrays were washed, 
stained in the Aﬀ ymetrix ﬂ uidics station and scanned with 
117 patients with vCJD vs 84 in-house controls from UK National Blood 
Service genotyped with Aﬀymetrix 500k and 100k arrays with a 
dynamic model (DM) algorithm
35 top-ranked SNPs genotyped with MGB probes
119 patients with vCJD vs 3692 UK controls (2999 from Wellcome Trust 
Case Control Consortium and 730 from UK National Blood Service)
506 sCJD vs 3692 UK controls (as above)
28 iCJD vs 3692 UK controls (as above)
151 patients with kuru (aged <25 years vs >25 years)
125 elderly women who are resistant to kuru vs 562 healthy young Fore
17 SNPs linked to PRNP and 1325 spaced autosomal SNPs that are not 
      associated with vCJD, genotyped with a GoldenGate genotyping assay
119 patients with vCJD vs 344 UK controls from the European Collection 
of Cell Cultures
485 patients with sCJD vs 344 UK controls (as above)
28 patients with iCJD vs 344 UK controls (as above)
143 patients with kuru (aged <25 years or >25 years at onset)
122 elderly women who are resistant to kuru vs 282 healthy young Fore  
117 patients with vCJD vs 3083 UK controls (2999 from Wellcome Trust 
Case Control Consortium and 84 from UK National Blood Service) 
genotyped with Aﬀymetrix arrays by use of a Bayesian robust linear 
model with Mahalanobis distance classiﬁer algorithm
Figure 1: Flowchart of the genotyping in the tiered study
For each tier, the patient and control sample collections used are subsets of 
those genotypes in the minor groove-binding (MGB) probe study. In the ﬁ rst 
two tiers, the 117 samples from patients with vCJD are a subset of the 119 used 
in tiers three and four. In the second tier, the 84 samples from the UK National 
Blood Service are a subset of the 730 used in the third tier. In the ﬁ nal tier, the 
485 samples from patients with sCJD, the 143 samples from patients with kuru, 
the 122 samples from elderly women, and the 282 samples from healthy young 
Fore are all subsets of the samples used in the third tier. 
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a confocal laser-scanning microscope (GeneChip Scanner 
3000 System with Workstation and Autoloader).
The following sample comparisons were made in the 
association studies: vCJD versus UK controls genome-
wide with Aﬀ ymetrix array data; vCJD, sCJD, and iCJD 
versus UK controls in a validation and replication study 
with minor groove-binding [MGB] probes; healthy elderly 
women who were exposed to kuru at mortuary feasts 
versus geographically matched young individuals from the 
Eastern Highlands of Papua New Guinea in the replication 
study; young patients with kuru versus older kuru patients 
in the replication study. Figure 1 shows the tiered nature of 
the study. Subsets of each sample group have been used in 
previous studies of PRNP codon 129.18 The comparison of 
young versus old patients with kuru was based on a 
hypothesis derived from mouse models that states that 
genetic factors control the incubation time of human prion 
diseases.12 The incubation time of middle-aged or elderly 
patients who died of kuru at the peak of the epidemic 
cannot be calculated with precision and might have been 
many decades. Incubation times of up to 50 years or longer 
have been recorded in recently diagnosed patients,5 
whereas children, adolescents, or young adults have a 
limited incubation time.5 Because the kuru collection was 
a mixture of samples from young and old patients, we 
hypothesised a priori that greater diﬀ erences would be 
found between young people with kuru and old people 
with kuru than between people with kuru versus modern 
young healthy Fore. This strategy was supported by the 
precedent of homozygosity at codon 129 of PRNP, which 
was strongly associated with young versus old kuru, but 
was not signiﬁ cant in a comparison of all kuru with healthy 
Fore. 
Genotyping and statistical analysis
We used the Aﬀ ymetrix 100K and 500K arrays (early access, 
EA-500K), which use four restriction enzymes in total. Our 
ﬁ rst case–control study used data generated by the 
Aﬀ ymetrix DM (dynamic model) algorithm from 
117 samples of patients with vCJD (two samples were not 
suitable for use with Aﬀ ymetrix arrays) and 90 UK controls 
matched for birthplace. The 500K product is comprised of 
two arrays each of about 250K digested with the restriction 
endonucleases NspI or StyI; the 100K product is comprised 
of two arrays each of about 50K digested with the restriction 
endonucleases XbaI and HindI. Genotypes were called by 
the dynamic model (DM) and subsequently by BRLMM 
algorithms. Samples from patients with vCJD were 
repeated if the DM call rate was less than 85% or the 
BRLMM call rate was less than 90% and samples were 
excluded if they underperformed by these criteria (vCJD 
[n=0], NBS [n=6], WTCCC [n=5]). The median and mean 
BRLMM call rates (all non-WTCCC samples and all arrays) 
were 99·0% and 98·5%. No samples were excluded for 
excess or low heterozygosity. One duplicate sample but no 
related individuals were identiﬁ ed. With genome-wide 
SNP data, the PLINK toolset for whole-genome association 
and population-based linkage analysis enables estimates of 
the relatedness of individuals. For the purposes of 
conﬁ rming unrelatedness, this can be expressed as a 
probability for identity by descent (IBD)=0 using complete 
linkage agglomerative clustering. This probability was 
greater than 0·75 for all study pairwise comparisons. No 
samples were identiﬁ ed as ethnic outliers by use of identity 
by state clustering. 
Genotype data quality analysis and ﬁ ltering was done 
with PLINK. From 598 676 unﬁ ltered SNPs, the following 
were excluded from further analysis by standard quality 
control: monomorphic SNPs or those not genotyped by 
EA-500K or WTCCC arrays (n=170 334); greater than 10% 
missing genotypes in vCJD (n=66 659) or WTCCC 
(n=9828); evidence of Hardy–Weinberg disequilibrium 
(exact test, p<0·001) in our UK samples (n=4873) or (exact 
test, p<1·0×10–⁵) in WTCCC samples (n=7673); minor 
allele frequency less than 0·01 in vCJD and WTCCC 
samples (n=57 853); allelic test for diﬀ erences in our in-
house UK samples versus WTCCC (p<0·001; n=1888). 
After this trimming, 410 287 SNPs remained for testing in 
117 patients with vCJD versus 3083 UK controls (84 in-house 
UK controls and 2999 WTCCC samples). A more stringent 
ﬁ lter applied additional thresholds of less than 3% missing 
data overall, and minor allele frequencies greater than 3% 
(n=288 908 SNPs remaining). These stringently ﬁ ltered 
data were assessed for whether the skewed quartile–
quartile (QQ) plots (ﬁ gure 2) were caused by cryptic 
population stratiﬁ cation between the UK control and vCJD 
groups or alternatively by inaccurate SNP genotyping. The 
absence of a signiﬁ cantly skewed QQ plot in the stringently 
ﬁ ltered data supports the hypothesis that SNPs were 
inaccurately called, probably on the EA-500K platform. 
Subsequently this was conﬁ rmed by concordance testing 
with the GoldenGate platform. 
Candidate SNPs for further study were identiﬁ ed in 
stringently ﬁ ltered dataset or after standard ﬁ ltering if 
there was additional evidence of genotype accuracy, by 
identifying an association signal in nearby SNPs in strong 
linkage disequilibrium with the candidate SNP. As a 
further test to identify false-positive associations related to 
diﬀ erential genotyping accuracy between cases and 
controls, we validated (>99% concordance) all genotypes 
shown in vCJD and in-house UK controls with an 
independent platform (MGB probe and quantitative PCR) 
before attempting replication in other categories of prion 
disease with the same technology (35 SNPs were tested in 
this way). To maximise coverage, a further 17 SNPs were 
chosen from the PRNP locus  (by maximising pairwise r² 
with HapMap build 35 using Haploview) and genotyped 
with GoldenGate technology. In total 52 SNPs were 
genotyped for association studies further to the discovery 
phase.
PLINK was used for association and permutation 
testing. The primary analysis was an allelic χ² test with 
use of empirical p values if any cell count was less 
than 15. A secondary analysis implemented genotypic, 
For the PLINK toolset  see 
http://pngu.mgh.harvard.edu/
~purcell/plink/index.shtml
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dominant, and recessive models, with empirical 
signiﬁ cance if necessary, controlling for the four tests 
done. Imputation of codon 129 genotype was done by 
the PLINK proxy-impute command (multimarker 
tagging) with dense SNP data around PRNP, including 
rs1799990, generated in 344 in-house UK controls. A 
nominal genome-wide signiﬁ cance threshold of p<5×10–
⁷ was used in the primary analysis in concordance with 
the WTCCC. Owing to the large number of SNPs that 
were tested, this threshold takes into account multiple-
hypothesis testing. In the replication phase of the study, 
the small number of tested SNPs permits a less stringent 
threshold of p<0·001.
Population structure was analysed with IBS clustering 
(implemented through PLINK) and principle components 
analysis (implemented through the Eigenstrat package19). 
Genome-wide data that were ﬁ ltered to high stringency 
were used to compare samples from patients with vCJD 
and UK controls with PLINK and Eigenstrat (no 
signiﬁ cant eigenvectors were detected with default 
procedures). A separate low-density study was done with 
GoldenGate technology for several reasons: to investigate 
genotype accuracy in the SNPs ﬁ ltered out by the high-
stringency ﬁ ltering step; to provide evidence with regard 
to the population structure in the samples from Papua 
New Guinea, which was previously unknown; to provide 
evidence that concordant genotypes consistent with the 
healthy population frequencies could be obtained from 
the ampliﬁ ed degraded samples from patients with kuru. 
17 additional SNPs were genotyped to provide dense 
coverage of the PRNP locus, which is a region that 
confers susceptibility to prion disease, with a high 
probability of novel susceptibility being discovered here. 
These 17 SNPs complemented an existing dataset of 
25 SNPs from the earlier genome-wide phase of the 
study. SNPs were selected from standard stringency 
ﬁ ltered data in the genome-wide phase of the study; all 
autosomes were equally represented, with a median 
intermarker distance of 1·3 Mb. 1523 individuals were 
genotyped for 1325 SNPs: 344 randomly selected, non-
related, white blood donors from the UK provided by the 
ECCCs; 119 patients with vCJD; 485 patients with sCJD; 
28 patients with iCJD; 143 patients with kuru; 122 elderly 
women who are resistant to kuru and were born before 
1950; and 282 young individuals from the kuru region 
matched to the elderly women by village of residence 
(ﬁ gure 1). These patients were a subset of those included 
in the replication studies. SNPs were ﬁ ltered for 
association with vCJD by comparison with UK controls 
by best permuted p<0·001 from any of four genetic 
models (allelic, trend, genotypic, or recessive) with the 
GoldenGate platform at the St Bartholomew’s Hospital 
Genome Centre. Genotyping quality was assessed by 
Hardy–Weinberg equilibrium (excluding those assessed 
by exact test p<0·001) and visual inspection of all 
genotype clusters with Beadstudio version 3.1. The overall 
genotype call rate was 99·7%, and concordance of 
duplicate samples was excellent (nine WGA2 degraded 
ampliﬁ ed kuru samples [concordance 99·7%] and 
20 healthy control duplicates [concordance >99·9%]). 
This study conﬁ rmed that the skew in the QQ plots was 
caused by inaccurate genotyping of SNPs in our genome-
wide study that were not adequately ﬁ ltered by the low-
stringency criteria. For Eigenstrat, ten eigenvectors were 
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Figure 2: QQ (quartile–quartile) plots of diﬀ erent stages of quality control
(A) Unﬁ ltered allelic χ² test of vCJD samples versus all UK samples (internal and Welcome Trust Case Control Consortium [WTCCC]) data. (B) Standard ﬁ ltering allelic χ² 
test of vCJD versus all UK samples (internal and WTCCC data). (C) Standard ﬁ ltering with allelic χ² test of vCJD versus only internal UK samples. (D) High-stringency 
ﬁ ltering. With standard ﬁ ltering, the inﬂ ation factor used for genomic control of confounding factors was estimated as 1·06 (1·01–1·09). Red dots=observed data. Blue 
lines=expected data. Broken blue lines=95% CI for expected data.
For more on the Genome Centre 
see http://www.
bartsandthelondon.nhs.uk/
research/core_facilities_to_
support_research.asp#genome
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generated through default procedures and outlier 
detection (6 of 826 samples from Papua New Guinea 
were removed). No signiﬁ cant eigenvectors (p>0·01) 
were identiﬁ ed between patients with  sCJD or iCJD and 
UK controls, or between patients with kuru, elderly 
women who are resistant to kuru, and healthy young 
Fore (ﬁ ve comparisons in total).
 The Gene Expression Analysis Software (MAS 5.0) was 
used to analyse the raw image ﬁ les from the quantitative 
scanning, which resulted in ﬁ les that contained background 
corrected values for the probes. Signiﬁ cance analyses to 
compare prion versus mock-infected cells used a two-class 
unpaired test with a Benjamini–Hochberg (false discovery 
rate) p-value correction. 
Role of the funding source
The sponsors had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. Simon Mead and John Collinge had full access 
to all the data in the study and ﬁ nal responsibility for the 
decision to submit for publication. 
Results
After standard quality control for call rate and minor allele 
frequency, Hardy–Weinberg disequilibrium, and 
diﬀ erences between control datasets, we analysed 
410 287 SNPs in the primary analysis. QQ plots showed an 
excess of large allelic χ² test statistics (ﬁ gure 2) owing partly 
to the comparison between cases and controls among 
platforms and laboratories and was completely resolved by 
stringent ﬁ ltering by call rate and minor allele frequency, 
leaving  about 300K SNPs for association testing. 
Comparison of these stringently ﬁ ltered data between 
vCJD and our own UK controls, ECACC controls, and 
WTCCC controls with Eigenstrat and GC methods did not 
provide evidence of signiﬁ cant population stratiﬁ cation; 
therefore, association statistics were not corrected. 
Similarly, we found no evidence of population stratiﬁ cation 
in comparisons of 1325 SNPs in replication cohorts (sCJD, 
iCJD, and control groups from the UK) or between patients 
with kuru, elderly women who were resistant to kuru, and 
healthy Fore from Papua New Guinea. In the stringently 
ﬁ ltered data, two SNPs were signiﬁ cant at the genome-
wide level (p<5×10–⁷) on the basis of allelic tests: rs6107516 
in the intron of PRNP and rs6794719 in an intergenic 
region between RARB and THRB, which encodes thyroid 
hormone receptor beta (ﬁ gure 3).
A block of linkage disequilibrium that was larger than 
~100 kb and included all of PRNP was shown by 25 SNPs 
(ﬁ gure 3). We added 17 more SNPs from vCJD and UK 
controls, including PRNP codon 129 (rs1799990). 
Unsurprisingly, rs6107516, which is located in the intron of 
PRNP and is in moderately strong linkage disequilibrium 
with codon 129 (rs1799990, r²=0·6), was the top-ranked 
single SNP in the discovery phase. All patients with vCJD 
who have been genotyped to date are homozygous for 
Chromosome Locus Minor allele Major allele vCJD genotypes UK control genotypes Model p (vCJD) OR
rs1799990 20 4628251 G A 119/0/0 294/324/81 A 2·0×10!²⁷ ··
rs6107516 20 4625092 A G 117/2/0 1960/1227/227 A 2·5×10!¹⁷ 38·5 (9·6–155·2)
rs6116492 20 4646626 T G 104/12/1 2979/104/0 A 8·2×10!⁵ 3·71 (2·09–6·59)
rs1460163 8 80390003 A G 7/25/86 31/657/2734 R 5·6×10!⁵ 6·9 (3·0–16·0)
rs6794719 3 24777543 T A 3/31/84 346/1465/1596 A 1·9×10!⁷ 2·5 (1·7–3·7)
Genetic models: A=allelic; G=genotypic.
Table 1: Discovery tests of rs1799990 and four novel candidate SNPs in patients with vCJD and UK controls
iCJD 
genotypes
UK control 
genotypes
Model p (iCJD) sCJD 
genotypes
Model p (sCJD)
rs1799990 4/13/11 294/324/81 A 2·7×10!⁴ 307/98/101 G 2·3×10!²¹
rs6107516 9/12/7 1960/1227/227 R 0·002 320/100/55 G 3·6×10!¹¹
rs6116492 28/0/0 2979/104/0 A 0·62 483/22/0 A 0·30
rs1460163 0/7/21 31/657/2734 A 0·66 7/93/396 A 0·83
rs6794719 1/8/19 346/1465/1596 A 0·03 61/207/207 A 0·08
Genetic models: A=allelic; G=genotypic; R=recessive. 
Table 3: Replication tests of rs1799990 and four novel candidate SNPs in patients with iCJD, patients 
with sCJD, and UK controls 
Resistance to kuru despite exposure Early-onset and late-onset kuru Combined p value*
Elderly women 
exposed to kuru
Healthy 
young Fore
Model p value Young kuru 
(age <25 years)
Older kuru 
(age >25 years)
Model p value (kuru 
incubation)
rs1799990 16/86/23 112/287/163 G 0·001 16/18/25 9/71/12 G 9·1×10!⁸ 2·2×10!⁹
rs6116492 80/37/2 393/151/18 A 0·848 47/11/0 57/20/0 A 0·44 ··
rs1460163 30/77/16 140/144/40 R 2·5×10−4 23/29/5 26/42/23 A 0·017 5·7×10!⁵
rs6794719 5/47/63 26/118/136 A 0·12 4/25/27 7/33/47 A 0·687 ··
Genetic models: A=allelic; G=genotypic; R=recessive. *Fisher’s method.
Table 2: rs1799990 and three novel candidate SNPs in samples from Papua New Guinea
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rs1799990A (MM at PRNP codon 129). rs6107516 was most 
strongly associated in an allelic model (p=2·5×10–¹⁷; 
OR 38·5, 95% CI 9·6–155·2).
From the 25 SNPs in the discovery phase, codon 129 of 
PRNP was best tagged by a two SNP haplotype formed by 
rs6031692 and rs6107516 (r²=0·7, based on Hapmap build 
35 data) with a haplotypic association of p=1×10–²⁴. To test 
for more association at the locus, we conditioned for the 
association of codon 129 by imputing this genotype and 
including only methionine-homozygous UK controls from 
the WTCCC series. We thus identiﬁ ed evidence of 
additional genetic risk at this locus. rs6116492, which is 
downstream of PRNP and also in strong linkage 
disequilibrium with rs1799990, had a frequency of  0·06 in 
patients with vCJD and 0·017 in UK controls (allelic model 
p=8·2×10–⁵; 0·022 in 1544 UK controls with an imputed 
codon 129 methionine homozygous genotype; allelic 
model p=0·001, OR 2·63, 95% CI 1·43–4·82). rs6116492 is 
located in an intergenic region between PRNP and PRND, 
which encodes prion-like protein doppel. Genetic risk 
factors for sCJD have previously been identiﬁ ed upstream 
and downstream of PRNP but not for vCJD.20,21 Because we 
cannot guarantee that the rs1799990 genotype has been 
imputed perfectly, we also compared cases of vCJD (n=119) 
with in-house UK controls genotyped at rs1799990 and 
rs6116492 (n=701); we again found a signiﬁ cant, 
independent association of rs6116492, both by haplotype 
test conditioned on codon 129 (PLINK, likelihood ratio test 
with one degree of freedom; p=0·037), or simply by 
excluding controls with methionine/valine or valine/valine 
encoded at codon 129 genotypes followed by an allelic test 
(119 patients with vCJD vs 294 in-house UK controls with 
the genotype that encodes methionine/methionine at 
codon 129; p=0·02). SNP-1368 (rs1029273C, 24 466 base 
pairs upstream of codon 129), which we and others have 
conﬁ rmed to be associated with sporadic CJD but not 
vCJD, also showed no evidence of association with vCJD 
independent of codon 129.20,21
Because we tested the entire collection of samples 
from white British patients with vCJD (the majority of 
cases of vCJD), we then looked to closely related prion 
diseases to replicate independently and more broadly 
candidate SNPs with risk of prion disease. We tested for 
the association of rs6794719, rs6116492, and 33 other top-
ranking SNP associations from the vCJD study in 
patients with iCJD who were exposed to prion disease 
through cadaver-derived growth hormone therapy versus 
UK controls (n=28); 506 patients with sCJD—a worldwide 
disease of uniform incidence that aﬀ ects about 
1–2 million people per year—versus UK controls. We 
also tested patients with kuru and healthy elderly women 
who were exposed to but survived the kuru epidemic 
from the Eastern Highlands Province of Papua New 
Guinea. In the groups from Papua New Guinea, we 
tested whether candidates for genetic risk of vCJD were 
associated with kuru incubation time (by comparison 
with a cohort of young-onset kuru [n=59] versus old-
onset kuru [n=92]) or resistance to kuru, by comparison 
of elderly female survivors (n=125) with the young 
population (n=280–526). Homozygosity at codon 129 of 
PRNP was signiﬁ cantly associated with risk of iCJD 
(p=2·7×10–⁴), sCJD (p=2·3×10–²¹ ), and tests done in 
Papua New Guinea (Fisher’s method p=2·2×10–⁹; 
tables 1 and 2).
rs6794719A was associated with the risk of vCJD at a 
nominal genome-wide signiﬁ cance of p=1·9×10–⁷. The 
more frequent allele, rs6794719A, was also associated with 
disease risk in the small collection (n=28) of patients with 
iCJD (p=0·030; table 3) but not those with sCJD, kuru, or 
resistance to kuru. 
From the 33 top-ranked SNPs that failed to achieve 
genome-wide signiﬁ cance in patients with vCJD, the 
strongest overall evidence of association in replication 
cohorts was for rs1460163 (combined p=6·3×10–⁸ by 
Fisher’s method across orally acquired prion disease 
categories [combination of vCJD and Papua New Guinea 
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Figure 3: Physical location and p of allelic test and best of four genetic models 
(A) SNPs between THRB and RARB, including rs6794719. (B) SNPs upstream of STMN2 including rs1460163. (C) SNPs at the PRNP locus, including rs1799990, rs6107516, and rs6116492, showing 
trend test (ﬁ lled circles) and a test comparing vCJD with UK controls with codon 129 methionine homozygous genotypes (empty circles [imputed for WTCCC controls]).
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tests]). rs1460163 was associated with age of kuru onset 
(p=0·017) and resistance to kuru (p=2·5×10–4), with the 
same highest-ranking risk allele for vCJD and kuru. 
rs1460163 is located in a large block of linkage 
disequilibrium that extends just 5´ to  STMN2 (ﬁ gure 3). 
Other SNPs tested in the replication phase were either 
poorly genotyped in the discovery phase (concordance 
<99%), or showed no evidence of association in any prion 
disease category additional to vCJD (p>0·001; best from 
four risk models). 
We then analysed the clinical and molecular phenotype 
of UK prion disease for rs1460163, rs6116492, and 
rs6794719. In patients with sCJD, there was a signiﬁ cant 
modifying eﬀ ect of the risk allele, with clinical onset 5 years 
earlier for those with risk genotype rs1460163AA compared 
with those with GG (linear regression of log-transformed 
age of onset against genotype p=0·02; ﬁ gure 4). In patients 
with vCJD, the mean age of onset for genotype AA was 
3 years earlier than for those with GG, but this was not 
statistically signiﬁ cant (p=0·26). By use of a linear 
regression model with disease type as a factor, the 
rs1460163AA allele was associated with age of onset in 
sCJD and vCJD (log-transformed p=0·01) and was also 
independent of rs1799990. No eﬀ ect was seen on year of 
presentation, which in part will determine incubation time 
in vCJD, but this analysis is confounded by uncertainty in 
the time of exposure. No eﬀ ect was seen on sCJD PrPSc 
strain type as deﬁ ned by partial protease K digestion and 
western blot. rs6116492 and rs6794719 had no eﬀ ect on 
prion disease phenotype.
In a cellular model of mouse prion disease, the expression 
of Stmn2 was profoundly altered by infection with prions. 
This diﬀ erence was shown by comparison of the 
transcriptome of prion-infected and prion-uninfected cells 
in culture. Mouse hypothalamic neuronal (GT-1) cells that 
were infected with mouse brain homogenate (NBHMG) or 
RML-infected brain homogenate were analysed with the 
Aﬀ ymetrix Mouse Expression Array 430_2.0. Comparison 
of the expression between NBHMG and RML showed that 
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Figure 4: Age of clinical onset of vCJD (red) and sCJD (blue) patients against rs1460163 genotype
Clinical onset was deﬁ ned as the age of the ﬁ rst symptom that progressed into a neurological or neuropsychiatric 
condition due to prion disease. The central bars indicate mean age of onset; boxes indicate 95% CI of the mean.
Figure  5: Boxplot of Stmn2 and Rarb expression 
Expression of Stmn2 and Rarb in mouse neuronal cells (GT-1) treated with 
homogenate of healthy brain (NBHMG) or Rocky Mountain Laboratory scrapie 
brain homogenate (RML). Median is shown as a thick red horizontal line, IQR by 
boxes, and largest and smallest observations by whiskers.
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Stmn2 is signiﬁ cantly (p=3·6×10–¹⁸) downregulated by a 
factor of about 30 and ranked tenth out of more than 
21 537 genes that were represented by one or more 
transcripts on the array (ﬁ gure 5). In this study, the 
expression of 543 of 21537 (2·5%) genes was altered, with a 
fold change of more than 2·83 (corrected Benjamini–
Hochberg method). Neither RARB nor STMN2 is 
signiﬁ cantly expressed in human blood cells, which 
obviates the analysis of the correlation of gene expression 
with genotypic risk in a large collection of samples.
Discussion
We describe the ﬁ rst genome-wide study of genetic risk in 
a human prion disease and replication of a small number 
of top-ranking candidate SNPs. Further genetic studies of 
human prion disease, including more extensive replication 
studies, are warranted because our power was limited by 
the small size of the vCJD sample and an early generation 
platform was used. Owing to the rarity of the  disease, all 
available samples were used; the use of ampliﬁ ed DNA in 
a proportion of cases might have also aﬀ ected the quality 
of genotyping. For these reasons, we used highly stringently 
ﬁ ltered data and veriﬁ ed genotypes from candidate SNPs 
with an in-house assay. The potential exists for a larger 
scale study in sCJD that capitalises on decades of 
surveillance for human prion diseases across Europe and 
the rest of the world; however, this disease is undoubtedly 
more heterogeneous than vCJD.
The potential overlap in pathogenesis between vCJD and 
the other prion disease categories used in the replication 
phases of the study must also be considered. The 
pathogenesis of vCJD contrasts with the replication cohorts 
in terms of prion strain (all groups), tissue distribution, 
and route of infection (for iCJD and sCJD). Furthermore, 
in the case of our large collection from Papua New Guinea, 
the linkage-disequilibrium relationship between candidate 
SNPs and a putative functional SNP is not known and can 
therefore diﬀ er from that in the UK. For these reasons, an 
absence of association in one or more replication categories 
does not preclude a genuine association in vCJD. 
The precedent of codon 129 was important to inform the 
comparisons in the replication phase. All UK prion 
diseases have strong associations with homozygous 
genotypes; for vCJD, only the methionine homozygous 
genotype. However, the groups from Papua New Guinea 
are the most relevant in the replication phase because our 
only precedent of a major acquired human prion disease 
epidemic is kuru, which was historically transmitted by 
cannibalism and had a devastating eﬀ ect on the Fore and 
neighbouring linguistic groups of the Eastern Highland 
region of Papua New Guinea.5 Kuru was extensively 
documented at its peak in the mid-20th century.22 We 
ampliﬁ ed DNA from this archive and continued 
surveillance of kuru in the Fore in the late 20th century to 
identify recent cases of kuru with long incubation times 
and elderly Fore women with long-term survival after 
exposure to high doses of prions. At PRNP codon 129, 
elderly Fore women survivors of the kuru epidemic 
showed a profound Hardy–Weinberg disequilibrium, with 
an excess of the prion disease-resistance genotype 129MV 
relative to both homozygous genotypes 129MM and 
129VV. The patients with kuru show an age stratiﬁ cation 
of codon 129, with young patients being mostly genotype 
MM or VV and adult or elderly patients being mostly MV, 
consistent with a powerful eﬀ ect of codon 129 MV in 
extending kuru incubation time.5,23,24 Our study thus 
conﬁ rms the strong association of PRNP codon 129 
(rs1799990) across acquired and sporadic prion diseases as 
the outstanding genetic risk factor in human prion 
disease. Notably, the eﬀ ect was detectable in a small 
sample, which should be encouraging for those 
contemplating studies of rare diseases with well 
characterised patients and a distinct pathogenesis. 
The additional associations we report are not as strong or 
robust as those we conﬁ rm for PRNP codon 129 but each 
of these are beyond what would have been expected by 
chance when taking into account the problem with 
multiple testing. Although we cannot be certain that any of 
the three candidate SNPs we describe altered the expression 
of their nearest gene (PRNP, STMN2, or RARB), in each 
case these are excellent candidates for involvement in 
prion pathobiology. The risk conferred by rs6116492T could 
act through altered expression of PRNP owing to the 
crucial role for PrP in prion disease pathobiology; however, 
we have no direct evidence that a putative genetic risk 
conferred by rs1460163 or rs6794719 is manifest through 
their nearest genes (STMN2 or RARB) because these SNPs 
have no linkage disequilibrium with coding regions. 
Regulatory regions often act on nearby genes but can also 
act over great distances or even on diﬀ erent chromosomes, 
implicating other genes.25 
In the absence of further cohorts of orally acquired 
prion disease and taking into account the aforementioned 
caveats, we turn to functional evidence of a role for these 
candidate genes in prion disease. The expression of PrP 
in cultured neuronal and lymphoid cells is regulated by 
retinoic acid.26–28 Furthermore, the production of the 
disease-associated isoform of PrP (designated PrPSc) in 
cultured mouse neuronal cells infected with mouse 
prions is increased by treatment with retinoic acid.26 
Whether retinoic acid acts through the receptor encoded 
by RARB or another retinoic acid receptor for these 
biological activities is not known at present. In addition 
to PRNP, the strongest overall genetic evidence we found 
is for a SNP association upstream of STMN2. SCG10, the 
protein product of this gene, is a regulator of microtubule 
stability in neuronal cells, with potential implications for 
aggresome formation and modulation of prion 
neurotoxicity.29 We found that Stmn2 is turned oﬀ  by 
prion infection in mouse neuronal cells, in keeping with 
an early study,30 but diﬀ erent from a recent and rigorously 
conducted study.31 Whether prion infection or unknown 
experimental factors are responsible for this large eﬀ ect 
is unclear; a role for SCG10 in prion infection has not 
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been established and speculation about a mechanism in 
prion disease would be premature. 
Our data lend considerable support to the hypothesis that 
genetic susceptibility in addition to PRNP codon 
129 genotype has contributed signiﬁ cantly to the outbreak 
of vCJD to date. Whether these eﬀ ects are on the incubation 
period rather than susceptibility, such that further waves of 
BSE-associated prion disease with longer incubation 
periods might occur in the years ahead and be associated 
with diﬀ erent genotypes at many risk loci, is unknown.32
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